UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.058

Sortiert nach

Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor

Endocrinology (Philadelphia), 2005-11, Vol.146 (11), p.4609-4618

2005

Link zum Volltext

Verfügbarkeit prüfen

The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro

Endocrinology (Philadelphia), 2003-11, Vol.144 (11), p.5105-5117

2003

Link zum Volltext

Verfügbarkeit prüfen

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer

Journal of clinical pathology, 2007-11, Vol.60 (11), p.1216-1221

2007

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival

The Journal of pathology, 2009, Vol.217 (1), p.32-41

2009

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells

British journal of cancer, 2006-07, Vol.95 (2), p.172-180

2006

Link zum Volltext

Verfügbarkeit prüfen

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer

Reviews in endocrine & metabolic disorders, 2007-09, Vol.8 (3), p.241-253

2007

Link zum Volltext

Verfügbarkeit prüfen

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

Oncogene, 1998-10, Vol.17 (15), p.1949-1957

1998

Link zum Volltext

Verfügbarkeit prüfen

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

Endocrine-related cancer, 2004-12, Vol.11 (4), p.793-814

2004

Link zum Volltext

Verfügbarkeit prüfen

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications

Endocrine-related cancer, 2006-12, Vol.13 (Supplement_1), p.S77-S88

2006

Link zum Volltext

Verfügbarkeit prüfen

Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth

Breast cancer research and treatment, 2006-03, Vol.96 (2), p.131-146

2006

Link zum Volltext

Verfügbarkeit prüfen

Overview of tyrosine kinase inhibitors in clinical breast cancer

Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S135-S144

2005

Link zum Volltext

Verfügbarkeit prüfen

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy

Endocrine-related cancer, 2004-12, Vol.11 (4), p.623-641

2004

Link zum Volltext

Verfügbarkeit prüfen

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer

Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S29-S36

2005

Link zum Volltext

Verfügbarkeit prüfen

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

British journal of cancer, 2000-02, Vol.82 (3), p.501-513

2000

Link zum Volltext

Verfügbarkeit prüfen

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies

Journal of steroid biochemistry and molecular biology, 2005-02, Vol.93 (2), p.257-262

2005

Link zum Volltext

Verfügbarkeit prüfen

Development of strategies for the use of anti-growth factor treatments

Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S173-S182

2005

Link zum Volltext

Verfügbarkeit prüfen

Consensus Statement

Endocrine-related cancer, 2005-07, Vol.12 (Supplement_1), p.S1-S7

2005

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer

Clinical cancer research, 1999-08, Vol.5 (8), p.2069-2076

1999

Link zum Volltext

Verfügbarkeit prüfen

Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer

European journal of cancer (1990), 2007-01, Vol.43 (1), p.64-70

2007

Link zum Volltext

Verfügbarkeit prüfen

Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer

Annals of the New York Academy of Sciences, 2002-06, Vol.963 (1), p.104-115

2002

Link zum Volltext

Verfügbarkeit prüfen

Growth factor pathway switching: implications for the use of gefitinib and trastuzumab

Breast cancer online, 2006-07, Vol.9 (7), p.1-5, Article e27

2006

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer

The Journal of pathology, 1999-12, Vol.189 (4), p.514-520

1999

Link zum Volltext

Verfügbarkeit prüfen

Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

International journal of cancer, 1994-12, Vol.59 (5), p.619-628

1994

Link zum Volltext

Verfügbarkeit prüfen

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

International journal of cancer, 2000-03, Vol.85 (5), p.643-648

2000

Link zum Volltext

Verfügbarkeit prüfen

Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER− disease

Breast cancer online, 2004-10, Vol.7 (10), Article e28

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.058

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(941)
Mit Volltextzugriff
(918)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(690)
Life Sciences & Biomedicine
(490)
Humans
(382)
Female
(241)
Biological And Medical Sciences
(232)
Male
(199)
Medical Sciences
(175)
Physical Sciences
(147)
Animals
(129)
Middle Aged
(122)
Technology
(122)
Physics
(110)
Adult
(107)
Engineering
(93)
Aged
(87)
Oncology
(80)
Fundamental And Applied Biological Sciences. Psychology
(68)
Exact Sciences And Technology
(59)
Mice
(49)
Particle Collisions
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor

The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival

Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications

Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth

Overview of tyrosine kinase inhibitors in clinical breast cancer

Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies

Development of strategies for the use of anti-growth factor treatments

Consensus Statement

Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer

Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer

Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer

Growth factor pathway switching: implications for the use of gefitinib and trastuzumab

Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer

Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER− disease

Suchergebnisse filtern